AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

NEXT STORY
Global Veterinary Infectious Diseases Diagnostics Market Forecast to Grow at a CAGR of 7.98% to reach US$5.369 billion by 2025
PREV STORY
WISeKey “Foresight” IoT Early Warning System technologies can be used to facilitate the detection of future virus outbreaks
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Data Presented at the 11th IAS Conference on HIV Science Supports AREV’s Development of SUS-TAINN™, a Ready-to-Use Therapeutic Food to Treat Global Malnutrition and Starvation

author_avatar
NASDAQ Market News

Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association

LEXINGTON, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company ...

author_avatar
NASDAQ Market News

Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers

author_avatar
NASDAQ Market News